Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 2, 2002
Application of the AAA reaction to the synthesis of the furanoside of C-2-epi-hygromycin A: a total synthesis of C-2-epi-hygromycin ABarry M Trost, Joseph Dudash, Olivier DiratJournal of the American Chemical Society|August 29, 2002
Callipeltoside a: total synthesis, assignment of the absolute and relative configuration, and evaluation of synthetic analoguesBarry M Trost, Janet L Gunzner, Olivier Dirat, et al.Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.Journal of Pharmaceutical Sciences|April 26, 2026
Something in the air-Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessmentRok Grahek, Renat Selimov, Miha Drev, et al.Chemical Research in Toxicology|July 29, 2024
A Kinetic Model for Assessing Potential Nitrosamine CarcinogenicityShu Yu, J Christopher McWilliams, Olivier Dirat, et al.Pharmaceutical Research|September 4, 2024
Current Approaches to Design Space Development and Regulatory Applications for Drug Products: Findings from the IQ Utilization of Design Space for Filings Working Group SurveyJames E Miesle, Frederick Osei-Yeboah, Anette Pauli-Bruns, et al.Bioorganic & Medicinal Chemistry Letters|April 1, 2006
NK1 antagonists based on seven membered lactam scaffoldsJason M Elliott, Emma J Carlson, Gary G Chicchi, et al.Chemical Research in Toxicology|February 25, 2022
Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine ImpuritiesKrista L Dobo, Michelle O Kenyon, Olivier Dirat, et al.Nature Nanotechnology|January 17, 2025
Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticlesMatthew O'Brien Laramy, David A Foley, Roger H Pak, et al.Bioorganic & Medicinal Chemistry Letters|December 31, 2005
Novel lactam NK1 antagonists with anti-emetic activityGregory J Hollingworth, Emma J Carlson, José L Castro, et al.Pageof 2